๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

18 recruiting trials

for Pediatric Hereditary Kidney Diseases

Imaging Assessments of ARPKD Kidney Disease Progression NCT07201025n/a2 sites๐Ÿ“ Cleveland๐Ÿ“ Philadelphia The Cleveland Clinic The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children NCT06890143Phase 31 site๐Ÿ“ Shanghai Children's Hospital of Fudan University ยท Tests: Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks๏ผŒthen Standard Treatment alone for12 weeks, Staโ€ฆ Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies NCT01109394n/a5 sites๐Ÿ“ Washington D.C.๐Ÿ“ Orange๐Ÿ“ Bethesda National Cancer Institute (NCI) Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells NCT07148050Phase 11 site๐Ÿ“ Seattle Seattle Children's Hospital ยท Tests: SC-CAR.GPC3xIL15.21 CAR T cells Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) NCT04897321Phase 11 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells DFT383 in Pediatric Participants With Nephropathic Cystinosis NCT06910813Phase 1, Phase 26 sites๐Ÿ“ Phoenix๐Ÿ“ San Diego๐Ÿ“ Stanford Novartis Pharmaceuticals ยท Tests: DFT383 Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients NCT05944016Phase 316 sites๐Ÿ“ Heidelberg๐Ÿ“ Mรผnchen๐Ÿ“ Mรผnchen University Hospital Goettingen ยท Tests: Dapagliflozin, Placebo A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161Phase 216 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Washington D.C. Memorial Sloan Kettering Cancer Center ยท Tests: Selinexor A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors NCT05135975Phase 26 sites๐Ÿ“ Birmingham๐Ÿ“ Aurora๐Ÿ“ Washington D.C. Nationwide Children's Hospital ยท Tests: Cabozantinib Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis NCT06764602n/a1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702Phase 1, Phase 210 sites๐Ÿ“ Palo Alto๐Ÿ“ Aurora๐Ÿ“ Washington D.C. St. Jude Children's Research Hospital ยท Tests: Onivyde, Talazoparib, Temozolomide Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986Phase 247 sites๐Ÿ“ Los Angeles๐Ÿ“ Wilmington๐Ÿ“ Miami Travere Therapeutics, Inc. ยท Tests: Sparsentan, Sparsentan, Sparsentan Biomarkers of Resiliency In Childhood Cancer Surgery NCT06674811n/a1 site๐Ÿ“ Rochester Mayo Clinic ยท Tests: Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome NCT02378805n/a1 site๐Ÿ“ Gรถttingen University Hospital Goettingen ยท Tests: ACE-inhibitor, Angiotensin-receptor blocker (ARB), HMG-Coenzyme inhibitor (statin), Spironolactone or Finerenone, Paricโ€ฆ Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors NCT04715191Phase 11 site๐Ÿ“ Houston Baylor College of Medicine ยท Tests: CARE T cells Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190Phase 1, Phase 21 site๐Ÿ“ Gainesville University of Florida ยท Tests: Miltenyi CliniMACS Prodigy ยฎ system, Zoledronic acid Nephrological Outcome and Associated Congenital Anomalies in Pediatric Patients with Horseshoe Kidney NCT06728007n/a1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy